No abstract available
Publication types
-
Clinical Trial, Phase II
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / chemistry
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Cyclophosphamide / administration & dosage
-
Docetaxel
-
Doxorubicin / administration & dosage
-
Doxorubicin / analogs & derivatives
-
Drug Administration Schedule
-
Feasibility Studies
-
Female
-
Humans
-
Middle Aged
-
Neoadjuvant Therapy / methods*
-
Polyethylene Glycols / administration & dosage
-
Receptor, ErbB-2 / analysis
-
Receptors, Estrogen / analysis
-
Sample Size
-
Taxoids / administration & dosage
-
Trastuzumab
Substances
-
Antibodies, Monoclonal, Humanized
-
Receptors, Estrogen
-
Taxoids
-
liposomal doxorubicin
-
Docetaxel
-
Polyethylene Glycols
-
Doxorubicin
-
Cyclophosphamide
-
Receptor, ErbB-2
-
Trastuzumab
Associated data
-
ClinicalTrials.gov/NCT01206881